Short‐term changes in serum miRNA levels and patient‐reported clinical outcomes in myasthenia gravis
Muscle & Nerve · 2024-08 · 70 (2) · 284-289
DOI: 10.1002/mus.28177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, online erschienen am 10.06.2024. Verfasst von Yu-Fang Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Myasthenia Gravis, MicroRNAs, Patient Reported Outcome Measures, Quality of Life. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Erling-Persson Foundation.
Abstract (Originalsprache)
Introduction/Aims The circulating microRNAs (miRNAs) miR‐150‐5p, miR‐30e‐5p, and miR‐21‐5p have been suggested as potential biomarkers for myasthenia gravis (MG); however, the relationships between short‐term natural changes of the miRNAs and patient‐reported MG outcome scores have not been well‐studied. We assessed the short‐term fluctuations in miRNA levels and patient‐reported outcome measures in MG.
Methods
This prospective cohort study included 39 MG patients with regular follow‐ups and unchanged medications at the Neurology outpatient clinic at Uppsala University Hospital. Patients had weekly follow‐up visits for 1 month, at which blood samples were drawn, and scores from MG activities of daily living (MG‐ADL), MG quality‐of‐life‐15 (MG‐QoL15), and Fatigue Severity Scale (FSS) were assessed. Serum levels of miRNA miR‐150‐5p, miR‐30e‐5p, and miR‐21‐5p were analyzed using quantitative real‐time PCR.
Results
Intra‐individual levels of miR‐30e‐5p and miR‐150‐5p were stable, whereas a significant reduction in miR‐21‐5p was observed from week 1 to week 2 ( p = .0024) and from week 2 to week 3 ( p < .0001). There were intra‐individual differences over a short time in MG‐ADL, with higher scores in female patients ( p = .0281) and a significant reduction from the first to the second weeks ( p = .0281), whereas MG‐QoL15 and FSS scores were stable.
Discussion
The suggested MG biomarkers miR‐30e‐5p and miR‐150‐5p were more stable than miR‐21‐5p over a short time, indicating their short‐term stability as biomarkers. Prospective multi‐center studies with longer periods of follow‐up and matched controls are needed to validate these miRNAs as biomarkers in MG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden.
ORCID-Profile: Amol K Bhandage
Förderung
- Erling-Persson Foundation
Zitieren
APA
Huang, Y. F., Bhandage, A. K., Adeström, L. D., & Punga, A. R. (2024). Short‐term changes in serum miRNA levels and patient‐reported clinical outcomes in myasthenia gravis. Muscle & Nerve, 70(2), 284-289. https://doi.org/10.1002/mus.28177
Vancouver
Huang YF, Bhandage AK, Adeström LD, Punga AR. Short‐term changes in serum miRNA levels and patient‐reported clinical outcomes in myasthenia gravis. Muscle & Nerve. 2024;70(2):284-289. doi:10.1002/mus.28177
BibTeX
@article{Huang2024,
author = {Huang, Yu-Fang and Bhandage, Amol K and Adeström, Lisa Diaz-Pintado and Punga, Anna Rostedt},
title = {Short‐term changes in serum miRNA levels and patient‐reported clinical outcomes in myasthenia gravis},
journal = {Muscle & Nerve},
year = {2024},
volume = {70},
number = {2},
pages = {284--289},
doi = {10.1002/mus.28177}
}
EUVIMED